Your browser doesn't support javascript.
loading
Successful use of once-daily high-dose darunavir and dolutegravir in multidrug-resistant HIV.
Fulco, Patricia P; Leibrand Kaczmar, Crystal R; Gomes, Denese; Smith, Tima.
Affiliation
  • Fulco PP; Virginia Commonwealth University Health System, Richmond, Virginia.
  • Leibrand Kaczmar CR; Virginia Commonwealth University Health System, Richmond, Virginia.
  • Gomes D; Virginia Commonwealth University School of Pharmacy, Richmond, Virginia.
  • Smith T; Virginia Commonwealth University Health System, Richmond, Virginia.
J Clin Pharm Ther ; 45(2): 394-396, 2020 Apr.
Article in En | MEDLINE | ID: mdl-31765502
ABSTRACT
WHAT IS KNOWN AND OBJECTIVE? Antiretroviral (ARV) resistance may result during periods of consistently poor adherence. We report the successful use of a novel once-daily (QD) ARV regimen in a patient with multidrug-resistant (MDR) HIV. CASE

SUMMARY:

Once-daily darunavir 1200 mg/ritonavir 100 mg, dolutegravir and emtricitabine/tenofovir alafenamide was initiated with directly observed therapy. With the assistance of therapeutic drug monitoring, dolutegravir dosing was increased to 150 mg daily. The patient maintained virologic suppression for 18 months. WHAT IS NEW AND CONCLUSIONS? In this case, QD darunavir/ritonavir achieved similar trough concentrations to twice daily dosing with dolutegravir dose titration necessitated and resulted in HIV virologic control.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / Anti-HIV Agents / Darunavir / Heterocyclic Compounds, 3-Ring Language: En Journal: J Clin Pharm Ther Year: 2020 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Oxazines / Piperazines / Pyridones / HIV Infections / Anti-HIV Agents / Darunavir / Heterocyclic Compounds, 3-Ring Language: En Journal: J Clin Pharm Ther Year: 2020 Type: Article